Skip to main content

Table 4 Serological data for 167 subjects included in the study

From: An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab

Natallizumab treatment Number of patients Group False labeling pattern
Yes 20 2 17*
No 147 1-6 0
  1. *These patients were on natalizumab at the time blood samples were taken or stopped receiving this drug less than 6 months prior to collection of the blood sample.